The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 28, 2021

Filed:

May. 19, 2020
Applicant:

Vigene Biosciences Inc., Rockville, MD (US);

Inventor:

Zairen Sun, Rockville, MD (US);

Assignee:

Vigene Biosciences, Inc., Rockville, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/21 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/215 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/21 (2013.01); A61K 39/215 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/543 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/15041 (2013.01); C12N 2740/15051 (2013.01); C12N 2740/16041 (2013.01); C12N 2740/16061 (2013.01); C12N 2740/16062 (2013.01); C12N 2740/16211 (2013.01); C12N 2740/16222 (2013.01);
Abstract

The present invention is directed to recombinant lentiviral particles that array the SARS-CoV-2 spike (S) protein on their surface ('SARS-CoV-2 S Protein Lentiviral Particles'), and that optionally comprise an additional copy of a polynucleotide encoding the SARS-CoV-2 spike (S) protein in their viral genome, and to methods for the production of such lentiviral particles. The invention particularly pertains to such SARS-CoV-2 S Protein Lentiviral Particles that have been engineered to be incapable of mediating the integration of their lentiviral genome into the chromosomes of infected cells and/or to be incapable of mediating the reverse transcription of their lentiviral genome. The present invention is also directed to 'SARS-CoV-2 S Protein Lentiviral Vaccine' pharmaceutical compositions that comprise such SARS-CoV-2 S Protein Lentiviral Particles. The present invention is additionally directed to the use of such SARS-CoV-2 S Protein Lentiviral Vaccine pharmaceutical compositions for providing immunity to COVID-19 infection to humans and other mammals, either directly or as an inactivated form.


Find Patent Forward Citations

Sun, Zairen. (2021). Non-integratingcomprising mutant rt/in proteins and the sars-cov-2 spike protein (U.S. Patent No. 11129890). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11129890

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…